Alvotech (ALVO) said Monday the US Food and Drug Administration has issued certain observations following a routine surveillance inspection of its manufacturing facility in Reykjavik, Iceland.
"The company believes the observations can be addressed quickly and do not raise any substantial issues with the site or its operations," Alvotech said.
The company is "well positioned" to resubmit the relevant biologics license applications in the ongoing quarter and continues to expect FDA approval for the relevant applications during 2026, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments